Search

Your search keyword '"Senkus-Konefka, E."' showing total 134 results
Start Over Author "Senkus-Konefka, E."
134 results on '"Senkus-Konefka, E."'

1. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Author

Park, Y.H., Senkus-Konefka, E., Im, S.-A., Pentheroudakis, G., Saji, S., Gupta, S., Iwata, H., Mastura, M.Y., Dent, R., Lu, Y.-S., Yin, Y., Smruti, B.K., Toyama, T., Malwinder, S., Lee, S.C., Tseng, L.-M., Kim, J.H., Kim, T.-Y., Suh, K.J., Cardoso, F., Yoshino, T., and Douillard, J.-Y.

Published
2020
Full Text
View/download PDF

4. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Author

El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., Kallala, A., Arun, I., Azmoudeh-Ardalan, F., Fujimoto, L., Sua, L. F., Liu, S. -W., Lien, H. -C., Kirtani, P., Balancin, M., El Attar, H., Guleria, P., Yang, W., Shash, E., Chen, I. -C., Bautista, V., Do Prado Moura, J. F., Rapoport, B. L., Castaneda, C., Spengler, E., Acosta-Haab, G., Frahm, I., Sanchez, J., Castillo, M., Bouchmaa, N., Md Zin, R. R., Shui, R., Onyuma, T., Husain, Z., Willard-Gallo, K., Coosemans, A., Perez, E. A., Provenzano, E., Ericsson, P. G., Richardet, E., Mehrotra, R., Sarancone, S., Ehinger, A., Rimm, D. L., Bartlett, J. M. S., Viale, G., Denkert, C., Hida, A. I., Sotiriou, C., Loibl, S., Hewitt, S. M., Badve, S., Symmans, W. F., Kim, R. S., Pruneri, G., Goel, S., Francis, P. A., Inurrigarro, G., Yamaguchi, R., Garcia-Rivello, H., Horlings, H., Afqir, S., Salgado, R., Adams, S., Kok, M., Dieci, M. V., Michiels, S., Demaria, S., Loi, S., Schelfhout, V., Arbzadeh, E., Bondanar, A., Reyes, S. A. G., Ruz, J. R., Kang, J., Xiang, L., Zimovjanova, M., Togores, P., Ozturk, T., Patil, A., Corpa, M., Whitehouse, A., Tan, B., de Paula, A., Rossetti, C., Lang-Schwarz, C., Mahon, S., Giacometti, C., Linderholm, B., Deman, F., Montagna, G., Gong, G., Pavcovich, M., Chaer, Y., Cabrero, I. A., de Brito, M. L., Ilieva, N., Fulop, A., Souza, M., Bilancia, D., Idowu, M., Johri, R., Szpor, J., Bachani, L., Schmitt, F., Giannotti, M., Kurebayashi, Y., Ramirez, B. E. A., Salido, E., Bortesi, L., Bonetto, S., Elomina, K., Lopez, P., Sharma, V., Edirisinghe, A., Mathur, D., Sahay, A., Mouloud, M. A., Giang, C. H., Mukolwe, E., Kiruka, E., Samberg, N., Abe, N., Brown, M., Millar, E., X. B., Li, Yuan, Z., Pasupathy, A., Miele, R., Luff, R., e Porfirio, M. M. A., Ajemba, O., Soni, R., Orvieto, E., Dimaio, M., Thomas, J., Merard, R., Subramaniam, M. M., Apolinario, T., Preda, O., Preda, R., Makanga, A., Maior, M. S., Li, L., Saghatchian, M., Saurine, T., Janssen, E., Cochran, J., Vlada, N., Cappellesso, R., Elfer, K., Hollick, M., Desai, S., Oner, G., Schreurs, A., Liu, S., Perera, R., Mercurio, P., Garcia, F., Hosny, K., Matsumoto, H., van Deurzen, C., Bianchini, G., Coban, I., Jahangir, A., Rahman, A., Stover, D., Luz, P., Martel, A., Waumans, Y., Stenzinger, A., Cortes, J., Dimitrova, P., Nauwelaers, I., Velasco, M., Fan, F., Akturk, G., Firer, M., Roxanis, I., Schneck, M., Wen, H., Cockenpot, V., Konstantinov, A., Calatrava, A., Vidya, M. N., Choi, H. J., Jank, P., Ciinen, A. H., Sabanathan, D., Floris, G., Hoeflmayer, D., Hamada, T., Laudus, N., Grigoriadis, A., Porcellato, I., Acs, B., Miglietta, F., Parrodi, J., Clunie, D., Calhoun, B., F. -I., Lu, Lefevre, A., Tabbarah, S., Tran, W., Garcia-murillas, I., Jelinic, P., Boeckx, C., Souza, S., Cebollero, M. C., Felip, E., Rendon, J. L. S., El Gabry, E., Saltz, J., Bria, E., Garufi, G., Hartman, J., Sebastian, M., Olofsson, H., Kooreman, L., Cucherousset, J., Mathieu, M. -C., Ballesteros-Merino, C., Siziopikou, P., Fong, J., Klein, M., Qulis, I. R. I., Wesseling, J., Bellolio, E., Araya, J. C., Naber, S., Cheang, M., Castellano, I., Ales, A., Laenkholm, A. -V., Kulka, J., Quinn, C., Sapino, A., Amendoeira, I., Marchio, C., Braybrooke, J., Vincent-Salomon, A., Korski, K. P., Sofopoulos, M., Stovgaard, E. I. S., Bianchi, S., Bago-Horvath, Z., Yu, C., Regitnig, P., Hall, S., Kos, Z., Sant, S., Tille, J. -C., Gallas, B., Bethmann, D., Savas, P., Mendes, L., Soler, T., van Seijen, M., Gruosso, T., Quintana, A., Giltnane, J., Van den Eynden, G., Duregon, E., de Cabo, R., Recamo, P. C., Gaboury, L., Zimmerman, J., Pop, C. S., Wernicke, A., Williams, D., Gill, A., Solomon, B., Thapa, B., Farshid, G., Gilham, L., Christie, M., O'Toole, S., Hendry, S., Fox, S. B., Luen, S. J., Lakhani, S. R., Fuchs, T., John, T., Brcic, I., Hainfellner, J., Sigurd, L., Preusser, M., Poortmans, P., Decaluwe, A., Carey, C., Colpaert, C., Larsimont, D., Peeters, D., Broeckx, G., van de Vijver, K., Buisseret, L., Dirix, L., Hertoghs, M., Piccart, M., Ignatiadis, M., Van Bockstal, M., Sirtaine, N., Vermeulen, P., de Wind, R., Declercq, S., Gevaert, T., Haibe-Kans, B., Nelson, B. H., Watson, P. H., Leung, S., Nielsen, T., Shi, L., Balslev, E., Thagaard, J., Almangush, A., Makitie, A., Joensuu, H., Lundin, J., Drubay, D., Roblin, E., Andre, F., Penault-Llorca, F., Lemonnier, J., Adam, J., Lacroix-Triki, M., Ternes, N., Radosevic-Robin, N., Klaushen, F., Weber, K., Harbeck, N., Gluz, O., Wienert, S., Cserni, G., Vingiani, A., Criscitiello, C., Solinas, C., Curigliano, G., Konishi, E., Suzuki, E., Yoshikawa, K., Kawaguchi, K., Takada, M., Toi, M., Ishida, M., Shibata, N., Saji, S., Kogawa, T., Sakatani, T., Okamoto, T., Moriya, T., Kataoka, T., Shimoi, T., Sugie, T., Mukohara, T., Shu, Y., Kikawa, Y., Kozuka, Y., Sayed, S., Rahayu, R., Ramsaroop, R., Senkus-Konefka, E., Chmielik, E., Cardoso, F., Ribeiro, J., Chan, J., Dent, R., Martin, M., Hagen, C., Guerrero, A., Rojo, F., Comerma, L., Nuciforo, P., Serrano, V. V., Camaea, V. P., Steenbruggen, T., Ciompi, F., Nederlof, I., Jan, Hudecek, van der Laak, J., van den Berg, J., Voorwerk, L., van de Vijver, M., de Maaker, M., Linn, S., Mckenzie, H., Somaiah, N., Tutt, A., Swanton, C., Hiley, C., Moore, D. A., Hall, J. A., Le Quesne, J., Jabbar, K. A., al Bakir, M., Hills, R., Irshad, S., Yuan, Y., Li, Z., Liu, M., Klein, J., Fadare, O., Thompson, A., Lazar, A. J., Gown, A., Lo, A., Garrido Castro, A. C., Madabhushi, A., Moreira, A., Richardson, A., Beck, A. H., Bellizzi, A. M., Wolff, A., Harbhajanka, A., Sharma, A., Cimino-Mathews, A., Srinivasan, A., Singh, B., Chennubhotla, C. S., Chauhan, C., Dillon, D. A., Zardavas, D., Johnson, D. B., Thompson, A. E., Brogi, E., Reisenbichler, E., Huang, E., Hirsch, F. R., Mcarthur, H., Ziai, J., Brock, J., Kerner, J., Zha, J., Lennerz, J. K., Carter, J. M., Reis-Filho, J., Sparano, J., Balko, J. M., Pogue-Geile, K., Steele, K. E., Blenman, K. R. M., Allison, K. H., Pusztai, L., Cooper, L., Estrada, V. M., Flowers, M., Robson, M., Rebelatto, M. C., Hanna, M. G., Goetz, M. P., Khojasteh, M., Sanders, M. E., Regan, M. M., Misialek, M., Amgad, M., Tung, N., Singh, R., Huang, R., Pierce, R. H., Leon-Ferre, R., Swain, S., Ely, S., Kim, S. -R., Bedri, S., Paik, S., Schnitt, S., D'Alfons, T., Kurkure, U., Bossuyt, V., Tong, W., Wang, Y., Dos Anjos, C. H., Gaire, F., Van Diest, P. J., El Bairi, Khalid [0000-0002-8414-4145], de Freitas, Juliana Ribeiro [0000-0003-4978-7273], Sur, Daniel [0000-0002-0926-4614], Amendola, Luis Claudio [0000-0002-6404-450X], Azmoudeh-Ardalan, Farid [0000-0003-4701-0532], Kirtani, Pawan [0000-0002-2343-7016], Yang, Wenxian [0000-0002-5349-9680], Castillo, Miluska [0000-0002-0111-3176], Provenzano, Elena [0000-0003-3345-3965], Mehrotra, Ravi [0000-0001-9453-1408], Ehinger, Anna [0000-0001-9225-7396], Rimm, David L [0000-0001-5820-4397], Bartlett, John MS [0000-0002-0347-3888], Denkert, Carsten [0000-0002-2249-0982], Hida, Akira I [0000-0002-4486-8819], Sotiriou, Christos [0000-0002-5745-9977], Hewitt, Stephen M [0000-0001-8283-1788], Badve, Sunil [0000-0001-8861-9980], Symmans, William Fraser [0000-0002-1526-184X], Goel, Shom [0000-0001-8329-9084], Francis, Prudence A [0000-0002-7207-9286], Horlings, Hugo [0000-0003-4782-8828], Salgado, Roberto [0000-0002-1110-3801], Demaria, Sandra [0000-0003-4426-0499], Loi, Sherene [0000-0001-6137-9171], Apollo - University of Cambridge Repository, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'anatomie pathologique, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), and UNICANCER

Subjects
Oncology, medicine.medical_treatment, [SDV]Life Sciences [q-bio], TRASTUZUMAB, Improved survival, MICROENVIRONMENT, Review Article, SUBTYPES, NEOADJUVANT CHEMOTHERAPY, 0302 clinical medicine, Breast cancer, Ecology,Evolution & Ethology, PROGNOSTIC-SIGNIFICANCE, Medicine and Health Sciences, Pharmacology (medical), TUMOR-INFILTRATING LYMPHOCYTES, Stage (cooking), RC254-282, Chemical Biology & High Throughput, 0303 health sciences, Human Biology & Physiology, Genome Integrity & Repair, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ASSOCIATION, 3. Good health, 030220 oncology & carcinogenesis, Biomarker (medicine), Life Sciences & Biomedicine, Genetics & Genomics, medicine.medical_specialty, chemical and pharmacologic phenomena, International Immuno-Oncology Biomarker Working Group, Predictive markers, 03 medical and health sciences, Signalling & Oncogenes, SDG 3 - Good Health and Well-being, Internal medicine, 692/53/2423, medicine, Radiology, Nuclear Medicine and imaging, In patient, 030304 developmental biology, Computational & Systems Biology, Science & Technology, IDENTIFICATION, business.industry, review-article, Cancer, 03.01. Általános orvostudomány, Immunotherapy, Tumour Biology, medicine.disease, PREDICTIVE-VALUE, 692/4028/67/1347, Programmed death 1, business, FREE SURVIVAL
Abstract

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC. ispartof: NPJ BREAST CANCER vol:7 issue:1 ispartof: location:United States status: published

Published
2021
Full Text
View/download PDF

6. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

Author

Untch, M., Gelber, R.D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-yi, F., Constantin, C., Mayordomo, J.I., Su, C.-H., Yu, S.-Y., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T. Suarez, Srimuninnimit, V., Colleoni, M., Coates, A.S., Piccart-Gebhart, M.J., and Goldhirsch, A.

Published
2008
Full Text
View/download PDF

8. LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

Author

Harbeck, N., Rastogi, P., O'Shaughnessy, J., Boyle, F., Cortés, J., Rugo, H.S., Goetz, M.P., Hamilton, E.P., Huang, C., Senkus-Konefka, E., Tryakin, A., Neven, P., Huober, J., Wei, R.J., Andre, V., Muñoz, M., San Antonio, B., Shahir, A., Martin Jimenez, M., and Johnston, S.R.D.

Published
2023
Full Text
View/download PDF

9. 1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial

Author

Ruiz Vico, M., Wetterskog, D., Thakali, S., Orlando, F., Jayaram, A.K., Vainauskas, O., Castellano Gauna, D.E., Martins, K.D., Iwata, K., Gourgioti, G., Serikoff, A., Astrom, L., Matveev, V., Esen, A.A., Feyerabend, S., Senkus-Konefka, E., Gupta, S., Merseburger, A.S., Demichelis, F., and Attard, G.

Published
2023
Full Text
View/download PDF

11. 73P microRNA expression profiles of single hormone receptor-positive breast cancers

Author

Kunc, M., primary, Popeda, M., additional, Szalkowska, A., additional, Niemira, M., additional, Lacko, A., additional, Radecka, B.S., additional, Braun, M., additional, Pikiel, J., additional, Litwiniuk, M., additional, Pogoda, K., additional, Szwajkosz, A., additional, Izycka-Swieszewska, E., additional, Zaczek, A.J., additional, Biernat, W., additional, and Senkus-Konefka, E., additional

Published
2020
Full Text
View/download PDF

13. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

Author

Senkus-Konefka, E., primary, Domchek, S.M., additional, Im, S.A., additional, Xu, B., additional, Armstrong, A., additional, Masuda, N., additional, Delaloge, S., additional, Li, W., additional, Tung, N., additional, Conte, P., additional, Wu, W., additional, Goessl, C., additional, Runswick, S., additional, and Robson, M., additional

Published
2018
Full Text
View/download PDF

14. Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)

Author

Loibl, S, primary, Barinoff, J, additional, Seiler, S, additional, Decker, T, additional, Denkert, C, additional, Hardy-Bessard, A-C, additional, Senkus-Konefka, E, additional, Cognetti, F, additional, Palmieri, C, additional, Gelmon, K, additional, Luebbe, K, additional, Furlanetto, J, additional, Mueller, V, additional, Mundhenke, C, additional, Schmidt, M, additional, von Minckwitz, G, additional, Uhlig, M, additional, Burchardi, N, additional, and Thill, M, additional

Published
2018
Full Text
View/download PDF

15. OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice

Author

Delaloge, S., primary, Conte, P.F., additional, Im, S-A., additional, Senkus-Konefka, E., additional, Xu, B., additional, Domchek, S.M., additional, Masuda, N., additional, Li, W., additional, Tung, N., additional, Armstrong, A., additional, Wu, W., additional, Goessl, C., additional, Runswick, S., additional, and Robson, M., additional

Published
2017
Full Text
View/download PDF

16. OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC)

Author

Robson, M., primary, Ruddy, K.J., additional, Im, S-A., additional, Senkus-Konefka, E., additional, Xu, B., additional, Domchek, S.M., additional, Masuda, N., additional, Delaloge, S., additional, Li, W., additional, Tung, N., additional, Armstrong, A., additional, Wu, W., additional, Goessl, C., additional, Degboe, A., additional, and Conte, P.F., additional

Published
2017
Full Text
View/download PDF

20. 290P - OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC)

Author

Robson, M., Ruddy, K.J., Im, S-A., Senkus-Konefka, E., Xu, B., Domchek, S.M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., Wu, W., Goessl, C., Degboe, A., and Conte, P.F.

Published
2017
Full Text
View/download PDF

23. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

Author

Cardoso, Fatima, Bedard, Philippe L, Winer, Eric P, Pagani, Olivia, Senkus-Konefka, E, Fallowfield, Lesley J, Kyriakides, S, Costa, Aurora, Cufer, T, Albain, Kathy S, Piccart-Gebhart, Martine, ESO-MBC Task Force, Cardoso, Fatima, Bedard, Philippe L, Winer, Eric P, Pagani, Olivia, Senkus-Konefka, E, Fallowfield, Lesley J, Kyriakides, S, Costa, Aurora, Cufer, T, Albain, Kathy S, Piccart-Gebhart, Martine, and ESO-MBC Task Force

Abstract

Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy., Journal Article, Research Support, Non-U.S. Gov't, Review, SCOPUS: no.j, info:eu-repo/semantics/published

Published
2009

25. A breast international group survey of young breast cancer patients' attitudes towards the risk of loss of fertility related to adjuvant therapies. EORTC protocol 10002 – BIG 3-98.

Author

Neskovic-Konstantinovic, Z, primary, Gomez, H, additional, Senkus-Konefka, E, additional, Dirix, L, additional, Jerusalem, G, additional, Murray, E, additional, Bottomley, A, additional, Rampion, J, additional, Duez, N, additional, Demonty, G, additional, and Di Leo, A, additional

Published
2009
Full Text
View/download PDF

27. Gene copy numbers of HER family in breast cancer

Author

Wełnicka-Jaskiewicz, M., primary, żaczek, A., additional, Bielawski, K. P., additional, Jańkiewicz, J., additional, Badzio, A., additional, Olszewski, W., additional, Konopa, K., additional, Rhone, P., additional, Senkus-Konefka, E., additional, and Jassem, J., additional

Published
2007
Full Text
View/download PDF

29. 8/Porównanie standardowego (20 Gy/5x) i hypofrakcjonowanego (16 Gy/2x) paliatywnego napromieniania chorych na nieoperacyjnego, niedrobnokomórkowego raka płuca (NDRP): końcowe wyniki wieloośrodkowego badania randomizowanego

Author

Senkus-Konefka, E., primary, Dziadziuszko, R., additional, Bednaruk-Młyński, E., additional, Pliszka, A., additional, Kubrak, J., additional, Lewandowska, A., additional, Małachowski, K., additional, Wierzchowski, M., additional, Matecka-Nowak, M., additional, and Jassem, J., additional

Published
2004
Full Text
View/download PDF

30. 150. Multicenter, randomized study assessing the impact of amifostine on normal tissue tolerance during radiotherapy for head and neck cancer

Author

Senkus-Konefka, E., primary, Kowalczyk, A., additional, Badzio, A., additional, Bednaruk-Młyński, E., additional, Mądrzak, J., additional, Matuszewska, K., additional, Kawecki, A., additional, Pietrusińska, E., additional, Kędzierawski, P., additional, Rucińska, M., additional, Szutkowski, Z., additional, Kiprian, D., additional, and Jassem, J., additional

Published
2003
Full Text
View/download PDF

37. 36. A prospective, randomized study to compare the value of two fractionation schemes of palliative radiotherapy for inoperable non-small cell lung cancer

Author

Senkus-Konefka, E., primary, Jassem, J., additional, Bednaruk-Mlynski, E., additional, Dziadziuszko, R., additional, Kubrak, J., additional, Lewandowska, A., additional, Malachowski, K., additional, Wierzchowski, M., additional, Rzepecki, J., additional, Chyczewska, E., additional, and Matecka-Nowak, M., additional

Published
2001
Full Text
View/download PDF

40. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

Author

Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS, ESO-MBC Task Force, Cardoso, Fatima, Bedard, Philippe L, Winer, Eric P, Pagani, Olivia, Senkus-Konefka, Elzbieta, Fallowfield, Lesley J, Kyriakides, Stella, Costa, Alberto, and Cufer, Tanja

Abstract

Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

49. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Baas, P., Fennell, D., Kerr, K.M., Van Schil, P.E., Haas, R.L., Peters, S., ESMO Guidelines Committee, Cervantes, A., Pentheroudakis, G., Pavlidis, N., Stahel, R.A., Cardoso, F., Senkus-Konefka, E., Arnold, D., Horwich, A., Sessa, C., Colombo, N., Licitra, L., Buske, C., Ladetto, M., Peters, S., Blay, J.Y., Keilholz, U., Strasser, F., Hassan, A.A., Herrstedt, J., McGregor, K.H., Bramley, C., Lamarre, J., Wallace, M., Galli, A., and Jezdic, S.

Subjects
Humans, Lung Neoplasms/diagnosis, Lung Neoplasms/pathology, Lung Neoplasms/therapy, Mesothelioma/diagnosis, Mesothelioma/pathology, Mesothelioma/therapy, Pleural Neoplasms/diagnosis, Pleural Neoplasms/pathology, Pleural Neoplasms/therapy
Published
2015

50. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Girard, N., Ruffini, E., Marx, A., Faivre-Finn, C., Peters, S., ESMO Guidelines Committee, Cervantes, A., Pentheroudakis, G., Pavlidis, N., Stahel, R.A., Cardoso, F., Senkus-Konefka, E., Arnold, D., Horwich, A., Sessa, C., Colombo, N., Licitra, L., Buske, C., Ladetto, M., Peters, S., Blay, J.Y., Keilholz, U., Strasser, F., Hassan, A.A., Herrstedt, J., McGregor, K.H., Bramley, C., Lamarre, J., Wallace, M., Galli, A., and Jezdic, S.

Subjects
Biopsy, Humans, Neoplasms, Glandular and Epithelial/classification, Neoplasms, Glandular and Epithelial/diagnosis, Neoplasms, Glandular and Epithelial/pathology, Neoplasms, Glandular and Epithelial/therapy, Thymus Neoplasms/classification, Thymus Neoplasms/diagnosis, Thymus Neoplasms/pathology, Thymus Neoplasms/therapy
Published
2015

Catalog

Books, media, physical & digital resources
See catalog results